Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
accepted:
03
12
2023
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
The aim of this work was to evaluate the cost-effectiveness of faricimab against relevant therapeutic alternatives used in clinical practice for the treatment of diabetic macular oedema (DMO) in the UK. A state-transition (Markov) model, with health states based on visual acuity scores and treatment pathways, was developed to conduct cost-utility analysis of faricimab treat and extend (T&E) regimen versus ranibizumab pro re nata (PRN) and aflibercept PRN over a time horizon of 25 years. Comparison against bevacizumab PRN was considered in scenario analysis. Effectiveness data for faricimab was sourced from the pivotal YOSEMITE and RHINE double-blind randomised controlled trials, and from a network meta-analysis for comparators. Costs and (dis)utilities were taken from nationally published sources or literature. The base case included indirect costs (productivity gains, informal care) given the wider impacts of DMO on society. Sensitivity analyses were conducted. In the base case, faricimab T&E dominated ranibizumab PRN and aflibercept PRN, being more effective and resulting in cost savings (between 0.16 and 0.36 mean QALYs gained, and £5483-9655 mean cost savings). In scenario analysis, faricimab was more effective but costlier compared with bevacizumab, with an incremental cost-effectiveness ratio (ICER) of £8898 per QALY gained. Considering only healthcare payer costs, the ICER of faricimab compared with ranibizumab PRN was £7991 per QALY gained and faricimab dominated aflibercept PRN. Faricimab T&E has the potential to reduce the burden of vision loss on society, giving people living with DMO greater independence and contributing to increased healthcare system capacity. At a threshold of £20,000, faricimab T&E is cost-effective compared with relevant comparators, and potentially cost saving.
Identifiants
pubmed: 38438829
doi: 10.1007/s41669-023-00465-4
pii: 10.1007/s41669-023-00465-4
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.
doi: 10.1186/s40662-015-0026-2
pubmed: 26605370
pmcid: 4657234
WHO. Diabetes: World Health Organization; [cited 2022 Sep 21]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/diabetes .
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.
doi: 10.2337/dc11-1909
pubmed: 22301125
pmcid: 3322721
Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96(3):345–9.
doi: 10.1136/bjo.2011.204040
pubmed: 21602478
Whicher CA, O’Neill S, Holt RIG. Diabetes in the UK: 2019. Diabet Med. 2020;37(2):242–7.
doi: 10.1111/dme.14225
pubmed: 31901175
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119.
doi: 10.1016/j.diabres.2021.109119
pubmed: 34879977
Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol. 2012;19(1):4–12.
doi: 10.4103/0974-9233.92110
pubmed: 22346109
pmcid: 3277023
NICE. Overview | Ranibizumab for treating diabetic macular oedema: National Institute for Health and Care Excellence [cited 2022 Sep 21]. Available from: https://www.nice.org.uk/guidance/ta274 .
NICE. Overview | Aflibercept for treating diabetic macular oedema: National Institute for Health and Care Excellence; [cited 2023 March 22]. Available from: https://www.nice.org.uk/guidance/ta346 .
NICE. Overview | Brolucizumab for treating diabetic macular oedema: National Institute for Health and Care Excellence [cited 2022 Dec 13]. Available from: https://www.nice.org.uk/guidance/ta820 .
DH. Department of Health for England: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals 2022. Available from: https://www.gov.uk/drug-safety-update/brolucizumab-beovuv-risk-of-intraocular-inflammation-and-retinal-vascular-occlusion-increased-with-short-dosing-intervals .
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–55.
doi: 10.1016/S0140-6736(22)00018-6
pubmed: 35085503
NICE. Faricimab for treating diabetic macular oedema (TA799). Technology appraisal guidance: National Institute for Health and Care Excellence [cited 2022 Sep 23]. Available from: www.nice.org.uk/guidance/ta799 .
Pearce I, Bailey C, Fletcher E, Ghanchi F, Rennie C, Santiago C, et al. Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema. Eye (Lond). 2020;34(5):969–81.
doi: 10.1038/s41433-019-0615-8
pubmed: 31619777
BNF. Medicinal forms | Faricimab | Drugs British National Formulary [cited 2022 Sep 21]. Available from: https://bnf.nice.org.uk/drugs/faricimab/medicinal-forms/ .
BNF. Medicinal forms | Aflibercept | Drugs | BNF British National Formulary [cited 2022 Sep 21]. Available from: https://bnf.nice.org.uk/drugs/aflibercept/medicinal-forms/#solution-for-injection .
BNF. Medicinal forms | Ranibizumab | Drugs | BNF British National Formulary [cited 2022 Sep 21]. Available from: https://bnf.nice.org.uk/drugs/ranibizumab/medicinal-forms/ .
BNF. Medicinal forms | Bevacizumab | Drugs | BNF British National Formulary [cited 2022 Sep 21]. Available from: https://bnf.nice.org.uk/drugs/bevacizumab/medicinal-forms/ .
Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–310.
doi: 10.1002/hec.1148
pubmed: 16941543
NICE. NG82 Macular degeneration. Appendix J: Health economics: National Institute for Health and Care Excellence 2018 [cited 2022 Sep 23]. Available from: https://www.nice.org.uk/guidance/ng82/evidence/appendix-j-health-economics-pdf-170036251093 .
NICE. TA799 Company evidence submission. Faricimab for treating diabetic macular oedema: National Institute for Health and Care Excellence 2022 [cited 2022 Dec 14]. Available from: https://www.nice.org.uk/guidance/ta799/evidence/committee-papers-pdf-11127510397 .
Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201–10.
doi: 10.1016/j.ophtha.2020.03.021
pubmed: 32402554
Kern C, Fu DJ, Huemer J, Faes L, Wagner SK, Kortuem K, et al. An open-source data set of anti-VEGF therapy in diabetic macular oedema patients over 4 years and their visual acuity outcomes. Eye (London). 2021;35(5):1354–64.
doi: 10.1038/s41433-020-1048-0
Watkins C, Paulo T, Bührer C, Holekamp NM, Bagijn M. Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis. Adv Ther. 2023:1-18.
Régnier S, Malcolm W, Allen F, Wright J, Bezlyak V. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. PLoS One. 2014;9(7): e102309.
doi: 10.1371/journal.pone.0102309
pubmed: 25029255
pmcid: 4100770
Christ SL, Lee DJ, Lam BL, Zheng DD, Arheart KL. Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling. Invest Ophthalmol Vis Sci. 2008;49(8):3318–23.
doi: 10.1167/iovs.08-1676
pubmed: 18362104
ONS. National life tables – life expectancy in the UK - Office for National Statistics: Office for National Statistics; [cited 2022 Sep 21]. Available from: ttps:// www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2017to2019 .
Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18(1):63.
doi: 10.1186/s12913-018-2836-0
pubmed: 29382329
pmcid: 5791217
NICE. Evidence Review Group Report | Aflibercept solution for injection for treating wet age‑related macular degeneration | Guidance | NICE: National Institute for Health and Care Excellence [cited 2022 Sep 21]. Available from: https://www.nice.org.uk/guidance/ta294/history .
NHSE. National Schedule of NHS costs. 2019/20 National Cost Collection Data Publication: NHS England; [cited 2022 Sep 21]. Available from: https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/ .
Jones KB, A. Costs of Health and Social Care 2021 2021 [cited 2022 Oct 24]. Available from: https://kar.kent.ac.uk/92342/25/Unit Costs Report 2021 - Final version for publication %28AMENDED2%29.pdf.
CADTH. CADTH Reimbursement Review: Faricimab (Vabysmo). 2023.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–9.
doi: 10.1016/j.ophtha.2016.02.022
pubmed: 26935357
UKDWP. State Pension age timetable - GOV.UK: UK Department for Work and Pensions; [cited 2022 Sep 21]. Available from: https://www.gov.uk/government/publications/state-pension-age-timetable/state-pension-age-timetable .
ONS. Annual Survey of Hours and Earnings time series of selected estimates: Office for National Statistics; 2021 [cited 2022 Sep 21]. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/ashe1997to2015selectedestimates .
ONS. A01: Summary of labour market statistics: Office for National Statistics; [cited 2022 Sep 21]. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/datasets/summaryoflabourmarketstatistics .
ONS. Disability and employment Office for National Statistics; [cited 2022 Sep 21]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/disability/datasets/disabilityandemployment .
Slade JE, E; Crawley, T; (Royal National Institute of Blind People). Employment for blind and partially sighted people in 2019 - RNIB 2022 [cited 2022 Sep 21]. Available from: https://www.rnib.org.uk/sites/default/files/Employment for blind and partially sighted people in 2019 - External version.docx.
Marques AP, Macedo AF, Hernandez-Moreno L, Ramos PL, Butt T, Rubin G, et al. The use of informal care by people with vision impairment. PLoS One. 2018;13(6): e0198631.
doi: 10.1371/journal.pone.0198631
pubmed: 29879193
pmcid: 5991749
Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12(5):793–9.
doi: 10.1111/j.1524-4733.2009.00527.x
pubmed: 19490557
NICE. NICE health technology evaluations: the manual. Processes and methods: National Institute for Health and Care Excellence 2022 [cited 2022 Sep 21]. Available from: https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741 .
Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118(1):47–51.
doi: 10.1001/archopht.118.1.47
pubmed: 10636413
Coyne KS, Margolis MK, Kennedy-Martin T, Baker TM, Klein R, Paul MD, et al. The impact of diabetic retinopathy: perspectives from patient focus groups. Fam Pract. 2004;21(4):447–53.
doi: 10.1093/fampra/cmh417
pubmed: 15249536
Gale R, Cox O, Keenan C, Chakravarthy U. Health technology assessment of new retinal treatments; the need to capture healthcare capacity issues. Eye (Lond). 2022;36(12):2236–8.
doi: 10.1038/s41433-022-02149-5
pubmed: 35764875
NHSDigital. Data on file: Hospital Outpatient Activity 2020-21: All Attendances, (September 2020). 2020.
ONS. Office for National Statistics population projections: Office for National Statistics; 2018. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/datasets/z3zippedpopulationprojectionsdatafilesengland
NHSDigital. Data on file: Hospital Outpatient Activity 2019-20: All Attendances, (October 2020). 2020.
NHSE. Data on file: Consultant-led Referral to Treatment Waiting Times Data 2021-22, Incomplete Commissioner Dec21 (February 2022) NHS England; Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/rtt-guidance/ .
NICE. Supporting the health and care system in improving productivity 2023 [cited 2023 5 May]. Available from: https://www.nice.org.uk/productivity .
Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil JR. Simulation modelling in ophthalmology: application to cost effectiveness of ranibizumab and aflibercept for the treatment of wet age-related macular degeneration in the United Kingdom. Pharmacoeconomics. 2017;35(2):237–48.
doi: 10.1007/s40273-016-0459-z
pubmed: 27787744
Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health. 2012;15(1):118–27.
doi: 10.1016/j.jval.2011.08.002
pubmed: 22264979
pmcid: 3268858
Butt T, Crossland MD, West P, Orr SW, Rubin GS. Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality. Br J Ophthalmol. 2015;99(4):540–4.
doi: 10.1136/bjophthalmol-2014-305802
pubmed: 25351679